Prime Therapeutics announces Ken Bodmer as chief financial officer

2023-12-05
高管变更
EAGAN, Minn., Dec. 5, 2023 /PRNewswire/ -- Today, Prime Therapeutics LLC/Magellan Rx Management LLC (Prime/MRx) announces that it has appointed Ken Bodmer as chief financial officer (CFO), effective Dec. 4, 2023.
Continue Reading
Prime Therapeutics announces Ken Bodmer as chief financial officer
Preview
来源: PRNewswire
Ken Bodmer, chief financial officer, Prime Therapeutics
"Ken is an extraordinary leader with a deep understanding of the markets we serve and brings a unique blend of financial and operational expertise coupled with a proven track record of success," said Mostafa Kamal, president and chief executive officer at Prime. "I've always believed the role of CFO is about much more than managing the numbers. It's about shaping the financial strategy of the company in ways that align with our core values and mission and Ken is the right person to do just that."
Bodmer has more than 20 years of experience in business and financial leadership in both pharmacy benefit management and specialty pharmacy. Prior to joining Prime/MRx, Bodmer most recently served as both president and CFO at PANTHERx Rare, a rare-disease pharmacy focused on caring for patients with complex conditions. Prior to joining PANTHERx, Bodmer held leadership positions at CVS Health. His previous experience also includes both CFO and chief operating officer roles at Accredo, as well as key financial leadership roles at Medco (now Express Scripts) and Catamaran (now OptumRx).
"I am honored to join Prime/MRx at such a pivotal time in the health care industry," said Bodmer. "Prime/MRx's capabilities, reach and unique vision position the company to reimaging pharmacy management at a time when it matters more than ever. I'm looking forward to being part of that success."
Bodmer completed his Master of Business Administration from Seton Hall University and his Bachelor of Science in Accounting from Villanova University. He is a member of the Financial Executive Institute, the Institute of Management Accountants, the American Institute of CPAs, and the Academy for Healthcare Management.
About Prime Therapeutics + Magellan Rx
Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization serving health plans, employers and government programs. Prime is collectively owned by 19 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Magellan Rx Management LLC, a Prime Therapeutics LLC Company, is a pioneer in specialty and medical drug management and a leader in serving public sector state government programs. Together Prime and Magellan Rx provide a wide range of clients with solutions that bridge the distance between medical and pharmacy management. For more information visit primetherapeutics.com and magellanrx.com or follow us on X (Twitter) at @Prime_PBM and @Magellan_Rx.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
适应症
-
靶点
-
药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。